PCL Inc is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Companyâ€™s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.

Employees

Sector

Biotechnology & Medical Research

More about the company

End-of-day quote Korea S.E. 21/03/2025			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

29/12/24	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
29/08/24	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Market Cap	16.8B 12.15M 10.44M 9.75M 8.92M 16.84M 1.16B 17.01M 115M 44.88M 584M 45.64M 44.65M 1.94B	P/E 2023	-7.17x	P/E 2024	-0.59x
Enterprise Value	23.83B 17.23M 14.8M 13.82M 12.66M 23.88M 1.65B 24.12M 164M 63.66M 828M 64.73M 63.33M 2.75B	EV / Sales 2023	22.8x	EV / Sales 2024	31.9x
Free-Float	98.99%	Yield 2023 *	-	Yield 2024	-

29/12/24	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
29/08/24	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI
21/08/24	PCL, Inc. announced that it expects to receive KRW 4.004999835 billion in funding	CI
24/06/24	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
20/06/24	Tiger Company Ltd. announced that it has received KRW 8.3 billion in funding from PCL, Inc.	CI
15/01/24	PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets	CI
25/12/23	PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets	CI
20/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets	CI
14/12/23	PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from JS & Partners Co., Ltd.	CI
31/05/23	South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13%	MT
31/05/23	PCL to Raise 36 Billion Won via Share Issuance	MT
23/03/23	PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
28/12/22	PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd.	CI

3 years	5,900	94,500
5 years	5,900	340,000
10 years	5,900	523,333.33

PCL, Inc. Share Price

Stocks

A241820

KR7241820000

Biotechnology & Medical Research

Valuation: PCL, Inc.

Latest news : PCL, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: PCL, Inc.

Bio Diagnostics & Testing

Financials

Company Profile

Manager	Title	Age	Since
So-Yeon Kim CEO	Chief Executive Officer	55	-
Seong-Woo Lee SAM	Sales & Marketing	42	27/03/2024
Mu-Yong So AUD	Comptroller/Controller/Auditor	53	27/03/2024

Director	Title	Age	Since
Chul-Joon Kim BRD	Director/Board Member	73	-
So-Yeon Kim BRD	Director/Board Member	55	-
Mu-Yong So BRD	Director/Board Member	53	27/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCL, INC.	-1.63%	-.--%	-.--%	-85.82%	12.12M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-1.69%	+3.27%	+96.54%	+293.08%	4.15B
IOVANCE BIOTHERAPEUTICS, INC.	-2.77%	+15.47%	+199.63%	+27.73%	3.76B
VERACYTE, INC.	-1.99%	+0.53%	+33.77%	+58.04%	3.4B
CAREDX, INC.	-2.28%	+4.81%	+266.23%	+441.62%	2.51B
BGI GENOMICS CO., LTD.	-0.71%	+3.10%	-21.61%	-20.34%	2.41B
FREENOME, INC.	-0.88%	+16.87%	+27.81%	-	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-2.43%	+47.89%	+244.08%	-20.25%	1.29B
SEEGENE, INC.	+5.41%	0.00%	+22.94%	+49.53%	1B
HANGZHOU ALLTEST BIOTECH CO., LTD.	-0.67%	-3.47%	-36.72%	+1.04%	552M
Average	-0.96%	+11.03%	+83.27%	+82.74%	2.06B
Weighted average by Cap.	-1.51%	+11.29%	+108.94%	+136.35%

	2023	2024
Net sales	8.43B 6.09M 5.23M 4.89M 4.48M 8.45M 584M 8.53M 57.93M 22.52M 293M 22.89M 22.4M 973M	1.25B 901K 774K 723K 662K 1.25M 86.31M 1.26M 8.56M 3.33M 43.32M 3.38M 3.31M 144M
Net income	-20.32B -14.69M -12.62M -11.78M -10.79M -20.36M -1.41B -20.56M -140M -54.27M -706M -55.18M -53.98M -2.34B	-52.34B -37.84M -32.5M -30.36M -27.79M -52.44M -3.62B -52.97M -360M -140M -1.82B -142M -139M -6.04B
Net Debt	7.2B 5.21M 4.47M 4.18M 3.83M 7.22M 499M 7.29M 49.51M 19.24M 250M 19.57M 19.14M 831M	7.03B 5.08M 4.37M 4.08M 3.73M 7.04M 487M 7.11M 48.31M 18.78M 244M 19.09M 18.68M 811M